Creative Biomolecules has named Jan Andrew Buck presidentand chief executive officer. He is a former vice president ofcorporate development with Bristol-Myers Squibb. CreativeBioMolecules of Hopkinton, Mass., focuses on development ofprotein-based therapeutics for repair and regeneration ofhuman tissues.
Cortex Pharmaceuticals Inc. of Irvine, Calif., has elected D. ScottHagen chief financial officer. Hagen will continue as corporatesecretary, a position he has held since August. Cortex(NASDAQ:CORX) is developing products for diagnosis andtreatment of age-related diseases and disorders of the brain.
Regeneron Pharmaceuticals Inc. of Tarrytown, N.Y., haspromoted four senior managers. Mark E. Furth, Ph.D., will bevice president of technology; Ronald M. Lindsay, Ph.D., will bevice president of neurobiology; Paul Lubetkin will be vicepresident, general counsel and secretary; and Dr. George D.Yancopoulos, Ph.D., will be vice president of discovery.Regeneron (NASDAQ:REGN) focuses on compounds to treatneurodegenerative diseases, peripheral neuropathies and nerveinjuries.
Cytel Corp. of San Diego has appointed Martin H. Goldstein vicepresident and general counsel; F. Jerry Volenec, Ph.D., directorof product development; and John B. Stoudemire, Ph.D., directorof safety evaluation. Goldstein was vice president and legalcounsel at Xoma Corp. Volenec was director of reagent productdevelopment at Becton Dickinson Immunocytometry Systems.Stoudemire was senior head of pharmacokinetics andtoxicology at Genetics Institute. Cytel (NASDAQ:CTEL) focuses ondrugs to treat immune system disorders and inflammatorydiseases.
MGI Pharma Inc. of Minneapolis has named Lori-Jean Gille vicepresident and general counsel. Gille joined the company fromDorsey & Whitney, a Minneapolis law firm. MGI Pharma(NASDAQ:MOGN) acquires, develops and marketspharmaceuticals prescribed and recommended by physicians.
Martha L. Hough has been promoted from corporate secretaryto vice president of planning and administration at GensiaPharmaceuticals Inc. She was appointed corporate secretarylast August. Nicholas Yeo has been named director of marketingfor Europe. Yeo had held marketing, regulatory and generalmanagement positions within Sterling-Winthrop from 1976 to1989. Gensia (NASDAQ: GNSA) of San Diego is abiopharmaceutical company.
(c) 1997 American Health Consultants. All rights reserved.